Caregiving Webinar with John Burhoe – Notes

Today, CurePSP (psp.org) hosted a wonderful webinar on caregiving with John Burhoe.  The presentation was a personal view of dealing with progressive supranuclear palsy (PSP) through the eyes of a veteran caregiver, John Burhoe.  John and his wife (Mary) Lou were married almost 45 years, “with the last five under the cloud of PSP.” He shared his story today because he wants to help prepare others going down this path.

Here are my notes.

Robin

————————————

John had two “advantages” not all have:
* ability to generate income while being home 24/7
* he is 6’3″, 225 lbs while Lou was 5’5″, 130 lbs.

The PSP journey began with Lou falling in the bathroom in 2002. They visited an MD at Scripps in San Diego. The MD’s diagnosis was “Parkinson’s Plus.” An MD at Mass General in Boston saw Lou three times; on the third visit, the diagnosis of PSP was given.

“The journey is much like a flight of stairs as opposed to a declining ramp with periods of relative stability punctuated by sudden and permanent drops.”

Example: In January 2007, Lou lost the ability to speak literally overnight. This ability never returned.

Lesson learned: Find multiple sources of support. These may not necessarily be where you would expect them.
* SSI (Sports, Spine & Industrial) is a facility in Greer, SC providing a combo of sports training, workout, and PT. Lou went twice a week. John could also work out at the same time.
* Church.
* Hospice.

Great aids:
* Portable aspirator ($250) – useful for choking spells
* Writing board is a great help in communicating. Also, ask yes/no questions (thumb up/down, or squeeze the finger).

Lesson learned: Educate yourself.
* curepsp.org: This website is being revised later this year and will be even better.
* Find other websites for info
* Support groups are a great source of info and comfort. Often caregivers get more out of these groups.

Lesson learned: Maintain the relationship.
* Look for and share the humor, albeit sometimes dark. John told the story of the “toilet tango” – dancing to the bathroom.

Lesson learned: Make sure others know the person behind the mask that you know. Introduce them to that person. NEVER let anyone refer to your loved one in the third person when he or she is sitting right there. (eg, “Does she want this?”) Nothing is more dehumanizing or degrading than that.

Lesson learned: Look out for “compassion stress and fatigue” and do something about it if this occurs.
* Short temper
* Depression
* Feeling sorry for yourself
* Social withdrawal
* Resentment towards your loved one
* Tears

Lesson learned: Take action.
* Ask for help. People want to help but you MUST tell them how.

Lesson learned: Take a “breather” to get away from the situation. And give your loved one a breather from you!
* You will lose your temper and say things you regret. You’re human – forgive yourself. Sounds easy, but it’s not.

Lesson learned: Don’t wait – do it now and for as long as you can. Examples: put a porch on the back of their house. Took car trips. Took airplane trips to visit grandchildren. The airlines are very helpful with wheelchair-bound passengers. Every day up until December 2007, John and Lou were in a car. They went to church up to the week Lou died.

Lesson learned: find a good local neurologist with whom you are both compatible.

Lesson learned: Allow yourself to have diversions.
* Three businesses with partners
* Promoting the concept of hospice
* Building awareness of PSP
* Reaching out to sister organizations for ALS, AD, and PD.

Lesson learned: Don’t feel sorry for yourself. What good will that do?
* Count your blessings and treasure the times you’ve had and still have together. John had a kitchen table filled with pictures of Lou and family and friends. Every time John walked by the table, he’d pause, look, and count his blessings.
* Right now focus on your loved one’s happiness.

Lesson learned: Be willing to fail. Whatever it is, try it. If it doesn’t work, and some won’t, at least you gave it a shot.

Issues you need to decide for yourself:
* whether to stay at home or utilize an extended care facility. This is often decided based on the physical size of the care giver and care recipient.
* whether to insert a feeding tube or not. Thoroughly research this, including having discussions with your MD. He recommended this website for some info on this decision: neurosy.org/disease/psp/psp-swallowing.html

Lesson learned: Don’t wait to get hospice involved! Get them involved early! John and Lou had hospice for 18 months.
* visit your local hospice organization and discuss the certification criteria
* major source of information, support, compassion, and experience
* Medicare covers this
* provides medical info, personal care, caregiver support, spiritual support
* you need an MD’s prescription

One day, Lou said: “I want to go home. Are you OK?” She said this after not having spoken for a year. The family gathered. Once the family was gathered, Lou died peacefully. (In 2008.)

John said that he felt relief in Lou’s passing. He pointed out that no one talks about this. Relief is “a natural phenomenon that everyone feels because a great load has been lifted from your shoulders and you now have your life back. No one talks about this but everyone experiences it.” After Lou died, for the first time in five years John had his own life back.

The five-year journey brought John closer to God.

Feelings and memories of his wife Lou are triggered by all sorts of things.

John established the “Mary Lou Burhue Scholarship Fund” to honor his wife and provide assistance to young people who mirror Lou’s core values of dignity, character, grace and humor in the face of adversity. Awards totaling over $20K have been made to 12 students.

John got married again about a year after his wife died. His new wife is Carolyn, Lou’s best friend of over 25 years. John responded to those who wondered about the “quick” re-marriage. John made two points. First, he had been grieving for Lou long before she died.

Second, John provided this quotation: “Your love for one person will never diminish your love for another. Love never divides, it always multiples.” — The late Dr. W.A. Criswell of Dallas

“Life goes on…honor your loved one by participating in it.”

Questions and Answers: (answers are by John Burhoe, unless indicated)

Q: Do PSP patients understand what is happening to them?
A: Yes – for Lou. This is not true for everyone.

A by Janet Edmunson: We need to act as if the loved one hears and understands everything.

Q: Since PSP and CBD are degenerative, what is the point of regular visits to the neurologist?
A: This is a dark view of things – saying “what’s the point?” Never give up. Never stop searching.

Q: Can you talk a little about your experience with sleep patterns and PSP/CBD?
A: John and Lou slept together throughout the disease. Neither John nor Lou had problems sleeping.

A by Janet Edmunson: Her late husband Charles (with pathologically-confirmed CBD; died at age 51) had terrible problems sleeping. Charles woke up hourly and he also moved around in bed a lot. The only medication that allowed him to sleep was Seroquel, an antipsychotic. Janet used TylenolPM for herself. Janet also slept on the floor next to the bed.

Q: Will you elaborate on your use of the portable aspirator?
A: It cost about $250. It took a long time to feed Lou. Liquids were thickened. Lou experienced one or two hour choking spells. These were more episodes of gagging, not coughing. The aspirator could be used to get some of the food out that had lodged in the throat.

Q: If you feel incompatible with your neurologist, what is the best way to find another one?
A: John did fire a neurologist from Duke. He found a local neurologist that both he and Lou liked.

A by Janet Edmunson: Use the PSP Forum to ask if anyone knows a neurologist.

A by Kate DeSantis, CurePSP: People can do a Google search on “movement disorder specialists.” Search on WeMove.org for MDs. Email Kate ([email protected]) for an MD referral. She has a list of MDs associated with the Movement Disorder Society.

A by participant: Referrals to local movement disorder specialists can be obtained through the APDA (American Parkinson Disease Association) Information & Referral Centers, apdaparkinson.org.

Q: Does/can hospice involve giving up therapies? PT, OT, speech? And meds?
A: Hospice doesn’t normally cover therapies. They

A by Janet Edmunson: If a therapy involves comfort or safety, hospice should cover it. You might get occupational therapy because they want to make sure the patient is safe in the home. Every hospice is different.

Q: Did Lou take antidepressants or other meds that you found helpful?

Q: What is the best way you found to prevent falls?
A: He’s not a good reference for this question. Lou’s first fall was her last fall. John is large enough that he was always able to prevent her falls.

A by Janet Edmunson: “Impulsivity” happens. Charles would get up on his own, despite being told that this was unsafe.

Q: What were your warning signs that Lou was nearing the end?
A: In Lou’s case, she decided when it was time to throw in the towel and she decided the time of her own death. In the last week, hospice put her on morphine. “People can very much pick the time and place of their death.” Lou “fought the good fight…and finished the course.”

Q: How did you communicate with Lou once she was unable to move her hands well?
A: John and Lou had been married a long time, he usually knew what she wanted. Lou was able to squeeze John’s finger up until the very end.

Q: What is your experience with vision problems?
A: Lou lost the ability to read very early. John and Lou got out a lot and attended many social events.

Q: What do you think is the best way that family members living away from the patient can be of help to the caregiver?
A: Visit, if you can. Sometimes giving money can be helpful. Let the caregiver and patient know that you care and you are there.

Q: A participant stated that a “transfer platter is helpful for moving patients between bed and chair, etc.” It was later described as a 12-14″ disc.
A: Neither John Burhoe nor Janet Edmunson were familiar with a “transfer platter.”

Q: Will you speak to how to handle inappropriate behavior in social situations?
A: Lou never behaved inappropriately. John feels blessed.

A by Janet Edmunson: Charles went through a stage of yelling, which was very uncharacteristic. He sometimes got agitated in public places. Humor might help. Sometimes they would just have to leave the restaurant or public place.

Janet told a story about Charles’s love for frozen yogurt. He would end up with frozen yogurt all over his face and clothes. They would just laugh about it. It was a special treat. So what if she had to wash his clothes after each outing?

Q: How did you explain the disease to your grandchildren?
A: His 5-year-old granddaughter didn’t require an explanation. The granddaughter just gave love to Lou, and Lou gave love back. Kids have wisdom and behavior beyond their years. Even the older grandkids didn’t require an explanation.

Gait and Balance Webinar Notes (5-28-09)

Did anyone attend this webinar on gait and balance webinar on May 28, 2009 and take notes (especially during the Q&A and when some photos were shown) that you can share?  It was at 2am in the timezone where I was that day, so I was unable to call in.

Though CurePSP was the organizer of this webinar, it applied to all the disorders in our group.

Today, as a registered attendee of the webinar, I received a copy of the slides.  I don’t think these have been posted yet to the CurePSP website (psp.org).

It seems from the slides that it was a very good webinar.  I’ve copied below the text from some of the slides shown during the webinar.

Here are some highlights from my perspective:

  • Assistive Device Golden Rule:  If you find yourself reaching out to touch walls, furniture, friends or care partners (or they are reaching to you) while walking–you are in need of an assistive device.
  • If falls continue no matter what we do, then safety gear may be the answer:  helmets; HipSaver®; chair or bed alarm; wheelchair; geriatric recliner chair.
  • How can PT and OT help?  Assess & treat functional mobility and ADL abilities.  Perform home safety assessments.  Develop new and safer ways to perform activities.  Train care-partners to safely assist.  Recommend appropriate adaptive equipment for the home.  Recommend appropriate mobility devices.

 

Robin

—————————————————————————-

Gait & Balance Questions Answered
by Heather Cianci, PT, MS, GCS, Penn Neurological Institute
5-28-09 CurePSP Webinar

Causes of Gait Changes & Falls
..Rigid/Stiff Muscles and Joints
..Shuffling steps
..Narrow base of support (feet too close)
..Slowed or absent balance reactions
..Slowness of Movement
..Visual Changes
–Difficulty with scanning your surroundings
–Double vision
..Loss of Coordination
..Freezing
..Blurred vision
..Orthostatic hypotension –sudden blood pressure drop
..“Alien limb”
..Myoclonus–quick, jerky movements
..Sensation changes
..Impaired safety judgment

Common Places Falls Occur
..Walking
..Turning
..On Stairs or Curbs
..While Reaching
..Transferring:
–In & out of bed
–In & out of the shower/bath tub
–In & out of the car
–Up & down from a chair or the toilet

Tips for Walking Safely
..Slow down & concentrate
–You must now “tell”your body what to do
–If you are unable to do this, it is important to have a care partner remind you
..To avoid shuffling
–Focus on landing with the heel hitting down first, not the toes
..Do one thing at a time
–Do not reach for the refrigerator door while walking toward it
..Keep your hands free
..Be aware of changes in the floor surface
–Tilt your head down to look at the floor
–Stop before the surface change and step over the threshold

Assistive Device Golden Rule
If you find yourself reaching out to touch walls, furniture, friends or care partners (or they are reaching to you) while walking–you are in need of an assistive device.

Getting Out of Bed
..Bend up knees
..Roll completely on your side
..Grab rail
..Allow your legs to drop off of the side of the bed…
..While you push yourself up sideways into sitting
..If help is needed, care partner can lift under shoulder & push down at outer thigh

Getting In & Out of the Car
To Safely Transfer
–Slide seat back
–Back into car & then slide legs in, reverse to get out
–Plastic bag on seat can make moving on fabric seats easier
–Place cushion on low seats to help with standing

Handy Bar (for gettign in and out of the car)
Allows for a safe place to hold
www.handybar.com, 888-738-0611

Sit to Stand Transfer
..Scoot to front of chair
..Open legs wide
..Pull feet back under the knees
..Lean forward –“Nose over Toes”
..Push forward until butt lifts off of chair
..Then push up to stand

Protection Products/Devices
If falls continue no matter what we do, then safety gear may be the answer…
Helmets
•http://www.cpsc.gov/CPSCPUB/PUBS/349.pdf(US Consumer Safety Product Commission brochure)
•www.headsaver.com.au
•Local sporting goods store
HipSaver®(shorts with hip and tailbone pads)
•www.hipsaver.com
•www.alimed.com or 800-225-2610
Chair or Bed Alarm
•Posey Sitter II®Alarm Unit
•www.posey.comor 800-447-6739
•Features different alarms or voice recording when person moves from chair or bed
Wheelchair or Geriatric Recliner Chair
•Contact local PT/OT or Rehabilitation Center to find a “Seating Clinic”or Wheelchair specialist

Rehabilitation Strategies
Current Research is Supporting
..Balance exercises
..Balance exercises along with eye movement training
..Treadmill and weight-supported treadmill training
..Group exercise programs
Exercise needs to be ongoing throughout the course of the disease. Delays in the need for wheelchairs, less falls, improvements in gait & balance, and reduced gait changes are possible.

How Can I Get More Help with Finding Assistive Devices?
RESNA (Rehabilitation Engineering & Assistive Technology Society of North America)
..www.resna.org
..“Projects”
..“Statewide AT Program”
..“State AT Program”or “Device Loan”
NATTAP (National Assistive Technology Technical Assistance Partnership)
..Locate programs available in each state
..703-524-6686

How Can I Find Someone to do Home Modifications?
Certified Aging-In-Place Specialist (CAPS)
..Certified specialist through The National Association of Home Builders
..Remodelers, Contractors, Interior Designers, Therapists
..800-368-5242
..www.nahb.org
–Resources –Online Directories –Find a CAPS

How Can PT and OT Help?
..Assess & treat functional mobility & ADL abilities
..Perform home safety assessments
..Develop new & safer ways to perform activities
..Train care-partners to safely assist
..Recommend appropriate adaptive equipment for the home
..Recommend appropriate mobility devices

Locating a PT or OT
..American PT Association
–1-800-999-2782
–www.apta.org
–“Find a Certified Specialist (Neurologic or Geriatric)”
..American OT Association
–301-652-2682
–www.aota.org
..LSVT®BIG
–888-438-5788
–www.lsvtglobal.com
–“Find a Clinician”
..Call Local Outpatient Rehab Centers
–Generally those associated with Hospitals (Regular & Rehabilitation), & non-sports oriented centers
–Ask if they have therapists who have worked with PSP or those who deal with neurological & balance problems
..We Move
–www.wemove.org
–“Find a Doctor”–Physical Medicine & Rehab
..National Parkinson Foundation
–800-327-4545
–www.parkinson.org
–Allied Team Training (ATTP)
–List of Graduates

Davunetide (aka, NAP, aka AL-108) trial now to focus on PSP

In November 2008, CurePSP, through the Pollin CBD Research Fund, awarded a research grant to UCSF and Dr. Boxer to study NAP (AL-108) in CBD. See:
http://forum.psp.org/viewtopic.php?t=7669

Within the last month or so I heard from a CBD family who plans to participate in the trial that UCSF would begin enrollment some time in the fall of 2009. There were to be at least two additional sites participating — Mayo Rochester and UPenn.

I heard a few days ago from Sharon, a local support group member, that the NAP trial would be open to PSPers. I received confirmation from UCSF today:

“After feedback from the European equivalent of the FDA, we were forced to focus on PSP, although we will still enroll a smaller number of CBD and FTD patients. The study will also be much larger than originally planned because of additional $ raised by the company that manufactures the drug. We are still the lead site and there will likely be 25 North American sites. More details about sites will be forthcoming in the next few months.”

UCSF emphasized that they have no further details to provide at this time. They did point me to a press release from Allon Pharmaceuticals, NAP’s manufacturer, that came out yesterday. I’ve copied that below.

One item I will clarify later is whether participating patients must have dementia or cognitive impairment.

Robin

http://allontherapeutics.com/ir_news_25Jun_2009.html

Allon Therapeutics forms Steering Committee for Phase II human trial

VANCOUVER — June 25, 2009 – Allon Therapeutics Inc. (TSX:NPC) reported today that leading neurologists and psychiatrists have joined a special Steering Committee to help the Company design and conduct a Phase II human clinical trial that will evaluate whether Allon’s lead neuroprotective drug candidate, davunetide intranasal (AL-108), has the potential to become the first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD). The study will evaluate the effect of davunetide for the treatment of Progressive Supranuclear Palsy (PSP), one type of FTD. A smaller study in other related forms of FTD will be carried out in parallel.

PSP is a degenerative brain disease that is often characterized by progressive difficulty with balance and walking, eye movement abnormalities, and cognitive and personality changes. PSP affects approximately 20,000 people in the United States, a patient population size consistent with an orphan drug designation. The company expects that efficacy in PSP would define the opportunity to use davunetide (AL-108) in other FTD subtypes that are tauopathies.

Gordon McCauley, President and CEO of Allon, said the Company plans to begin the Phase II trial in FTD during the second half of 2009.

“Physicians and researchers who specialize in FTD are enthusiastic about evaluating davunetide intranasal (AL-108) in FTD patients, primarily because about 50% of FTD and related disorders are tauopathies, or tau-related diseases — and Allon’s technology is recognized as the most clinically advanced tau-related therapy,” McCauley said.

The Company identified some of the members of its FTD Steering Committee as:

• Adam L. Boxer, M.D., Ph.D., Director of the University of California, San Francisco (UCSF) Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program and Assistant Professor of Neurology at the UCSF Memory and Aging Center, who specializes in Alzheimer’s Disease, Frontotemporal Dementia and related disorders such as Corticobasal Degeneration and Progressive Supranuclear Palsy.

• Rachelle S. Doody, M.D., Ph.D., Professor of Neurology and Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, Houston, who specializes in Alzheimer’s disease and memory disorders.

• Murray Grossman, M.D., Professor of Neurology and Psychiatry at the University of Pennsylvania School of Medicine, who specializes in the diagnosis and treatment of non-Alzheimer’s forms of dementia such as frontotemporal dementia, corticobasal degeneration, amyotrophic lateral sclerosis, and Lewy body disease.

• Anthony E. Lang, M.D., Director of the Division of Neurology and Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, and Director of the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital.

• Bruce L. Miller, M.D., Professor of Neurology at the University of California, San Francisco, A.W. & Mary Margaret Clausen Distinguished Chair, and Clinical Director of the UCSF Memory and Aging Center, which treats patients with diseases that cause dementia, including Alzheimer’s disease, corticobasal degeneration, Creutzfeldt-Jakob disease and frontotemporal dementia.

• Lon S. Schneider, M.D., Professor of Psychiatry, Neurology and Gerontology at the Keck School of Medicine of the University of Southern California, whose specialization includes Alzheimer’s disease and dementia.

FTD encompasses several cognitive disorders, including Behavioral Variant-Frontotemporal Dementia, Semantic Dementia and Progressive Nonfluent Aphasia, and the movement disorders, Corticobasal Degeneration and Progressive Supranuclear Palsy. No effective treatment is currently available for FTD, and several FTD syndromes are fatal within three to five years. FTD is often incorrectly diagnosed as Alzheimer’s disease.

In 2008, Allon reported efficacy results from a Phase IIa clinical trial that demonstrated that davunetide intranasal (AL-108) improved short-term and working memory performance in patients with amnestic mild cognitive impairment, a precursor to Alzheimer’s disease.

The pathology of Alzheimer’s disease and many forms of FTD has some similarities, including the presence of altered forms of the brain protein tau. In Alzheimer’s, altered tau forms tangles, part of the well-established plaques and tangles hallmarks of Alzheimer’s pathology. PSP is associated with “pure” tau pathology, unlike Alzheimer’s disease in which both amyloid and tau pathology is identified. This provides additional rationale for the use of AL-108 which targets tau in PSP.

Allon has shown that decreasing the levels of altered forms of tau with davunetide intranasal (AL-108) preserved the memory of mice bred to replicate Alzheimer’s or FTD pathology. Allon’s preclinical studies have also shown that davunetide intranasal (AL-108) preserved the memory and learning function of mice bred to replicate the altered tau pathology associated with FTD.

This trial at UCSF is now recruiting. Trial info was posted to clinicaltrials.gov about two weeks ago. See:
http://clinicaltrials.gov/ct2/show/NCT01056965

This is a 12-week study of davunetide (NAP, AL-108) or placebo is those with PSP, CBD, or two frontotemporal lobar degeneration disorders associated with tau pathology (FTDP-17 and PNFA). The drug and the placebo are both administered via nasal spray.

I noticed these two inclusion criteria may disqualify some:
* Subject resides outside a skilled nursing facility or dementia care facility. Residence in an assisted living facility is allowed.
* Able to ambulate with or without assistance.

And this exclusion criteria may disqualify some:
* Early, symptomatic autonomic dysfunction
* Within 4 weeks of screening or during the course of the study, concurrent treatment with memantine, acetylcholinesterase inhibitors, antipsychotic agents or mood stabilizers (valproate, lithium, etc.) or benzodiazepines (other than temazepam or zolpidem).
* Treatment with lithium, methylene blue, tramiprosate, ketone bodies, Dimebon or any putative disease-modifying agent directed at tau within 90 days of screening.
* Subject not willing to attempt LP [Robin’s note: LP probably means lumbar puncture.]

The UCSF trial contacts are:
Mary Koestler, RN, PhD, phone 415 476 0661, mkoestler AT memory.ucsf.edu
Arielle Lasky, phone 415 476 8333, alasky AT memory.ucsf.edu [Robin changed this from Nicholson to Lasky, as clinicaltrials.gov got updated]

Dr. Adam Boxer at UCSF’s MAC is the principal investigator.

I’ve heard from a few people (including one member here) that Mayo Jax intends to participate in this trial. Presumably this will happen later in 2010.

Robin

Will speech deteriorate over time?

I received this email earlier today:

“Mother seems to have all the major symptoms described with PSP except her speech. I can still understand everything she says easily (although her voice is weaker). Will this change over time too?”

Here’s my answer:

Probably though no one can be certain. People with the PSP-parkinsonism type of PSP don’t have dysarthria as a primary symptom. But these people often develop speech problems later on.

In a woman in our local support group who has PSP-P, her speech was understandable by me for the last couple of years. Now her voice has gotten so quiet that I can’t hear her, and no one else can either. She hardly speaks any more now.

No LRRK2 mutations in 88 PSP patients (Germany)

This recently-published abstract is on some German research into whether the LRRK2 genetic mutation occurs in PSP. This may be of most interest to those who participated in the 23andMe.com genetics testing.

I learned two things from the abstract:

* LRRK2 mutations “have been shown to be the most common genetic cause of both familial and sporadic Parkinson’s disease. Patients harboring LRRK2 mutations develop late onset PD that in most cases cannot be clinically distinguished from idiopathic PD.”

I thought LRRK2 was only associated with familial PD, and I thought familial PD was typically early-onset PD.

* “LRRK2 mutations have been reported to result in a broad spectrum of neuropathological alterations including progressive supranuclear palsy (PSP)-like Tau pathology.”

The weakness of this research is that the 88 PSP patients involved have a clinical diagnosis of PSP. The authors concluded that “there is no evidence that mutations in exon 31 of LRRK2 are a major risk factor for PSP. Our study, however, cannot rule out that other genetic variations in LRRK2 may be associated with PSP.”

Robin

European Journal of Neurology. 2009 Jun 15. [Epub ahead of print]

Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.

Madžar D, Schulte C, Gasser T.
Department of Neurodegenerative diseases, Hertie Institute for clinical brain research, University of Tuebingen, Tuebingen, Germany.

Background and purpose: Mutations in the leucine-rich repeat kinase gene (LRRK2) have been shown to be the most common genetic cause of both familial and sporadic Parkinson’s disease. Patients harboring LRRK2 mutations develop late onset PD that in most cases cannot be clinically distinguished from idiopathic PD.

Furthermore, LRRK2 mutations have been reported to result in a broad spectrum of neuropathological alterations including progressive supranuclear palsy (PSP)-like Tau pathology.

Methods: We screened a cohort of 88 clinically confirmed PSP patients for mutations in exon 31.

Results: We did not find any of the known mutations or any new variants.

Conclusions: Thus, there is no evidence that mutations in exon 31 of LRRK2 are a major risk factor for PSP. Our study, however, cannot rule out that other genetic variations in LRRK2 may be associated with PSP.

PubMed ID#: 19538213 (see pubmed.gov for this abstract only)